Tags

Type your tag names separated by a space and hit enter

Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study.
J Clin Psychopharmacol 1995; 15(1):12-9JC

Abstract

Forty-four patients with DSM-III-R generalized anxiety disorder participated in this double-blind, randomized study. Patients were on a benzodiazepine before the study and were stabilized on 3 to 5 mg/day lorazepam for 5 weeks (weeks 0 to 5). Thereafter, they were randomized to 15 mg/day buspirone or placebo for the following 6 weeks (weeks 6 to 11). During the first 2 weeks of double-blind, randomized treatment (weeks 6 to 7), lorazepam was tapered off. During weeks 12 to 13, patients received single-blind placebo. Assessment included the Hamilton Rating Scale for Anxiety, the State-Trait Anxiety Inventory, the Zung and Eddy Self-Rating Scale of Anxiety Symptoms, the Hamilton Rating Scale for Depression, and the Rome Depression Inventory, completed at weeks 0, 5, 6, 7, 8, 9, 11, and 13. Side effects were assessed through the Dosage Treatment Emergent Symptoms at the same times. The benzodiazepine-withdrawal syndrome was evaluated through a 27-symptom checklist (Clinical-Rated Benzodiazepine Withdrawal Symptom Schedule) at weeks 0, 5, 6, 7, 11, and 13. The results showed that buspirone was more effective than placebo and comparable to lorazepam. Buspirone-treated patients showed no rebound anxiety or benzodiazepine-withdrawal syndrome compared with placebo. Buspirone caused fewer side effects than lorazepam and was not different from placebo in this respect. Finally, buspirone maintained its anxiolytic effect for at least 2 weeks after the discontinuation of treatment.

Authors+Show Affiliations

III Cattedra di Clinica Psichiatrica, University La Sapienza Rome, Italy.

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

7714222

Citation

Delle Chiaie, R, et al. "Assessment of the Efficacy of Buspirone in Patients Affected By Generalized Anxiety Disorder, Shifting to Buspirone From Prior Treatment With Lorazepam: a Placebo-controlled, Double-blind Study." Journal of Clinical Psychopharmacology, vol. 15, no. 1, 1995, pp. 12-9.
Delle Chiaie R, Pancheri P, Casacchia M, et al. Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. J Clin Psychopharmacol. 1995;15(1):12-9.
Delle Chiaie, R., Pancheri, P., Casacchia, M., Stratta, P., Kotzalidis, G. D., & Zibellini, M. (1995). Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. Journal of Clinical Psychopharmacology, 15(1), pp. 12-9.
Delle Chiaie R, et al. Assessment of the Efficacy of Buspirone in Patients Affected By Generalized Anxiety Disorder, Shifting to Buspirone From Prior Treatment With Lorazepam: a Placebo-controlled, Double-blind Study. J Clin Psychopharmacol. 1995;15(1):12-9. PubMed PMID: 7714222.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. AU - Delle Chiaie,R, AU - Pancheri,P, AU - Casacchia,M, AU - Stratta,P, AU - Kotzalidis,G D, AU - Zibellini,M, PY - 1995/2/1/pubmed PY - 1995/2/1/medline PY - 1995/2/1/entrez SP - 12 EP - 9 JF - Journal of clinical psychopharmacology JO - J Clin Psychopharmacol VL - 15 IS - 1 N2 - Forty-four patients with DSM-III-R generalized anxiety disorder participated in this double-blind, randomized study. Patients were on a benzodiazepine before the study and were stabilized on 3 to 5 mg/day lorazepam for 5 weeks (weeks 0 to 5). Thereafter, they were randomized to 15 mg/day buspirone or placebo for the following 6 weeks (weeks 6 to 11). During the first 2 weeks of double-blind, randomized treatment (weeks 6 to 7), lorazepam was tapered off. During weeks 12 to 13, patients received single-blind placebo. Assessment included the Hamilton Rating Scale for Anxiety, the State-Trait Anxiety Inventory, the Zung and Eddy Self-Rating Scale of Anxiety Symptoms, the Hamilton Rating Scale for Depression, and the Rome Depression Inventory, completed at weeks 0, 5, 6, 7, 8, 9, 11, and 13. Side effects were assessed through the Dosage Treatment Emergent Symptoms at the same times. The benzodiazepine-withdrawal syndrome was evaluated through a 27-symptom checklist (Clinical-Rated Benzodiazepine Withdrawal Symptom Schedule) at weeks 0, 5, 6, 7, 11, and 13. The results showed that buspirone was more effective than placebo and comparable to lorazepam. Buspirone-treated patients showed no rebound anxiety or benzodiazepine-withdrawal syndrome compared with placebo. Buspirone caused fewer side effects than lorazepam and was not different from placebo in this respect. Finally, buspirone maintained its anxiolytic effect for at least 2 weeks after the discontinuation of treatment. SN - 0271-0749 UR - https://www.unboundmedicine.com/medline/citation/7714222/Assessment_of_the_efficacy_of_buspirone_in_patients_affected_by_generalized_anxiety_disorder_shifting_to_buspirone_from_prior_treatment_with_lorazepam:_a_placebo_controlled_double_blind_study_ L2 - http://Insights.ovid.com/pubmed?pmid=7714222 DB - PRIME DP - Unbound Medicine ER -